Lupus-Like Glomerulonephritis Associated With Regorafenib, a Multikinase Inhibitor

Hogan, 2015, Drug-induced glomerular disease: immune-mediated injury, Clin J Am Soc Nephrol, 10, 1300, 10.2215/CJN.01910215 Piga, 2014, Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort, Autoimmun Rev, 13, 873, 10.1016/j.autrev.2014.05.005 Grothey, 2013, Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, Lancet, 381, 303, 10.1016/S0140-6736(12)61900-X Jhaveri, 2016, Renal effects of novel anti cancer targeted therapies: a review of the FDA Adverse Event Reporting System, Kidney Int, 90, 705, 10.1016/j.kint.2016.06.027 Lopez, 2018, One drug, one patient, three lesions a case of regorafenib causing a triad of kidney injuries, Am J Kidney Dis, 71, 563 Li, 2015, Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 16, 619, 10.1016/S1470-2045(15)70156-7 Vasoo, 2006, Drug-induced lupus: an update, Lupus, 15, 757, 10.1177/0961203306070000 Akin, 1998, Minocycline-induced lupus in adolescents, Pediatrics, 101, 926, 10.1542/peds.101.5.926 McLaughlin, 1998, Rapid development of drug-induced lupus nephritis in the absence of extrarenal disease in a patient receiving procainamide, Am J Kidney Dis, 32, 698, 10.1016/S0272-6386(98)70039-3 Sarzi-Puttini, 2005, Drug-induced lupus erythematosus, Autoimmunity, 38, 507, 10.1080/08916930500285857 Short, 1995, Antigen specificity in hydralazine associated ANCA positive systemic vasculitis, QJM, 88, 775 Stokes, 2018, Full-house glomerular deposits: beware the sheep in wolf's clothing, Kidney Int, 93, 18, 10.1016/j.kint.2017.08.001 Naranjo, 1981, A method for estimating the probability of adverse drug reactions, Clin Pharmacol Ther, 30, 239, 10.1038/clpt.1981.154 Batchelor, 1980, Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility, Lancet, 1, 1107, 10.1016/S0140-6736(80)91554-8 Hess, 1988, Drug-related lupus, N Engl J Med, 318, 1460, 10.1056/NEJM198806023182209 Olsen, 2004, Drug-induced autoimmunity, Best Pract Res Clin Rheumatol, 18, 677, 10.1016/j.berh.2004.05.006 Yung, 1995, New concepts in the pathogenesis of drug-induced lupus, Lab Invest, 73, 746 Deng, 2003, Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling, Arthritis Rheum, 48, 746, 10.1002/art.10833 Chang, 2011, Drug-induced lupus erythematosus: incidence, management and prevention, Drug Saf, 34, 357, 10.2165/11588500-000000000-00000 Timlin, 2019, Clinical characteristics of hydralazine-induced lupus, Cureus, 11